Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 136


IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Elkabets M, Ribeiro VS, Dinarello CA, Ostrand-Rosenberg S, Di Santo JP, Apte RN, Vosshenrich CA.

Eur J Immunol. 2010 Dec;40(12):3347-57. doi: 10.1002/eji.201041037.


Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.

Park YJ, Song B, Kim YS, Kim EK, Lee JM, Lee GE, Kim JO, Kim YJ, Chang WS, Kang CY.

Cancer Res. 2013 Sep 15;73(18):5669-81. doi: 10.1158/0008-5472.CAN-13-0545. Epub 2013 Jul 18.


Expansion of CD11b(+)Ly6G (+)Ly6C (int) cells driven by medroxyprogesterone acetate in mice bearing breast tumors restrains NK cell effector functions.

Spallanzani RG, Dalotto-Moreno T, Raffo Iraolagoitia XL, Ziblat A, Domaica CI, Avila DE, Rossi LE, Fuertes MB, Battistone MA, Rabinovich GA, Salatino M, Zwirner NW.

Cancer Immunol Immunother. 2013 Dec;62(12):1781-95. doi: 10.1007/s00262-013-1483-x. Epub 2013 Oct 11.


Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.

Lu T, Ramakrishnan R, Altiok S, Youn JI, Cheng P, Celis E, Pisarev V, Sherman S, Sporn MB, Gabrilovich D.

J Clin Invest. 2011 Oct;121(10):4015-29. doi: 10.1172/JCI45862. Epub 2011 Sep 12.


MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.

Finke J, Ko J, Rini B, Rayman P, Ireland J, Cohen P.

Int Immunopharmacol. 2011 Jul;11(7):856-61. doi: 10.1016/j.intimp.2011.01.030. Epub 2011 Feb 11.


CpG blocks immunosuppression by myeloid-derived suppressor cells in tumor-bearing mice.

Zoglmeier C, Bauer H, Nörenberg D, Wedekind G, Bittner P, Sandholzer N, Rapp M, Anz D, Endres S, Bourquin C.

Clin Cancer Res. 2011 Apr 1;17(7):1765-75. doi: 10.1158/1078-0432.CCR-10-2672. Epub 2011 Jan 13. Erratum in: Clin Cancer Res. 2017 Feb 15;23 (4):1117.


The growing diversity and spectrum of action of myeloid-derived suppressor cells.

Mantovani A.

Eur J Immunol. 2010 Dec;40(12):3317-20. doi: 10.1002/eji.201041170.


Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells.

Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G.

J Immunol. 2008 Oct 1;181(7):4666-75.


Tumor-derived lactate modifies antitumor immune response: effect on myeloid-derived suppressor cells and NK cells.

Husain Z, Huang Y, Seth P, Sukhatme VP.

J Immunol. 2013 Aug 1;191(3):1486-95. doi: 10.4049/jimmunol.1202702. Epub 2013 Jul 1.


Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.

Mikyšková R, Indrová M, Polláková V, Bieblová J, Símová J, Reiniš M.

J Immunother. 2012 Jun;35(5):374-84. doi: 10.1097/CJI.0b013e318255585a.


Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4.

Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S.

J Leukoc Biol. 2009 Jun;85(6):996-1004. doi: 10.1189/jlb.0708446. Epub 2009 Mar 4.


Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Beury DW, Parker KH, Nyandjo M, Sinha P, Carter KA, Ostrand-Rosenberg S.

J Leukoc Biol. 2014 Dec;96(6):1109-18. doi: 10.1189/jlb.3A0414-210R. Epub 2014 Aug 28.


Subsets of myeloid-derived suppressor cells in tumor-bearing mice.

Youn JI, Nagaraj S, Collazo M, Gabrilovich DI.

J Immunol. 2008 Oct 15;181(8):5791-802.


Myeloid suppressor cell depletion augments antitumor activity in lung cancer.

Srivastava MK, Zhu L, Harris-White M, Kar UK, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S.

PLoS One. 2012;7(7):e40677. doi: 10.1371/journal.pone.0040677. Epub 2012 Jul 16. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/5c756e7d-6e97-416f-836a-dced97cf46af. Kar, Upendra [corrected to Kar, Upendra K].


Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.

Corzo CA, Cotter MJ, Cheng P, Cheng F, Kusmartsev S, Sotomayor E, Padhya T, McCaffrey TV, McCaffrey JC, Gabrilovich DI.

J Immunol. 2009 May 1;182(9):5693-701. doi: 10.4049/jimmunol.0900092.


Myeloid-derived suppressor cell function is reduced by Withaferin A, a potent and abundant component of Withania somnifera root extract.

Sinha P, Ostrand-Rosenberg S.

Cancer Immunol Immunother. 2013 Nov;62(11):1663-73. doi: 10.1007/s00262-013-1470-2. Epub 2013 Aug 27.


Myeloid-Derived Suppressor Cell Survival and Function Are Regulated by the Transcription Factor Nrf2.

Beury DW, Carter KA, Nelson C, Sinha P, Hanson E, Nyandjo M, Fitzgerald PJ, Majeed A, Wali N, Ostrand-Rosenberg S.

J Immunol. 2016 Apr 15;196(8):3470-8. doi: 10.4049/jimmunol.1501785. Epub 2016 Mar 2.


Regulatory T cells and myeloid-derived suppressor cells in the tumor microenvironment undergo Fas-dependent cell death during IL-2/αCD40 therapy.

Weiss JM, Subleski JJ, Back T, Chen X, Watkins SK, Yagita H, Sayers TJ, Murphy WJ, Wiltrout RH.

J Immunol. 2014 Jun 15;192(12):5821-9. doi: 10.4049/jimmunol.1400404. Epub 2014 May 7.


Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.

Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S.

Cancer Res. 2007 Oct 15;67(20):10019-26.

Supplemental Content

Support Center